# Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)

> **NCT04085666** · PHASE1 · COMPLETED · sponsor: **Société des Produits Nestlé (SPN)** · enrollment: 18 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** CDX 6114
- **OTHER:** Matching Placebo

## Key facts

- **NCT ID:** NCT04085666
- **Lead sponsor:** Société des Produits Nestlé (SPN)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-08-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085666, "Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04085666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*